Surname 1

Student's Name

Instructor's Name

Course Title

Submission Date

Angiotensin 2 Type-1 Receptor Blockers and Angiotensin I-converting Enzyme Inhibitors

on Survival of Patients With NSCLC.

Angiotensin enzyme inhibitors and angiotensin II receptor blocks are prescribed for a

range of od diseases. Hypertension, kidney diseases, and heart failures are various examples.

Vascular homeostasis plays a crucial role in maintaining the renin-angiotensin system. Type 2

receptors are stimulated(AT1R), increasingly vascular endothelial growth levels in

proangiogenically. Factor (VEGF) is essential in our test. Experiments on cell culture and animal

studies have indicated that antiproliferative effects at AT1R blockers and angiotensin I

converting enzyme inhibitors in some malignancies. Currently, there are very clinical data that is

available for a mixture of antineoplastic chemotherapy. A small number of patients suffering

from improved non-small cell lung cancer undergo chemotherapy with is first-line platinum-

based. Then the experiment was analyzed upon long time medication with ACEI And ARB.

Lisinopril and Captopril are the only ACE inhibitors that do not need to be activated in the body

to be effective. The researchers wanted to confirm the survival of patients.

Methodology

The coordinates' ethics committee clinically approved the experiment of Ruijin Hospital,

and the followed study methods followed the approved guidelines. As I review this article, Two
hundred twenty-eight patients were used as the sample size. All patients have improved, and

non-small-cell lung cancer, undergoing first-line platinum-based chemotherapy, stage 3, or 4. 73

of the patients underwent surgery before chemotherapy and had confirmed stage1,2, or 3. They

had received a first-line based platinum at least once. The hospital used the data of the patients

who had visited the facility, together with information on drugs, dosage, and timing of any

chemotherapy treatment they received. The performance for each patient was put into the record.

Follow-up data was obtained from the patient's file—ACEIs, ARBS, and beta-blockers, calcium

antagonists, and other drugs like antihypertensives. One hundred twelve patients received TKIs

treatment, either as a combination of chemotherapy or initial chemotherapy, and the data were

recorded appropriately.

The treatment results were promising in line with therapy. Survival was calculated from

day 1 to the patient's next visit or death. The aim of the experiment was the intent to give patients

treatment. Os was the period of the test to the end. There is a method known as Meier Kaplan

that we used to calculate a chance of survival. The chi-square test or Fisher's exact test was used

to compare categorical variables. SPSS was used to conduct statistical analysis.

Results From The Article.

From the first month of 2000 to the last month of 2014, 228 patients with advanced

NSCLC were given treatment with a platinum first line-based chemotherapy, 73 of them being

with different stages has undergone surgery before adjuvant chemotherapy. The sample size of

52 characters of ACEI/ARB and non--ACEI/ARB WERE 249 characters. One hundred twelve of

them received sequential treatment with TKIs. One hundred three affected obtained the

medication for hypertension, and 52 of them appropriated an ACEI with 25 samples or ARB

with 27 sample size. Drugs like antihypertensive and calcium blockers and other drugs have 40,4
and 7 sample sizes, respectively. Specialists listed antihypertensive doses, and I gave ten

patients a combination of the drugs in the facility. All of the patients continued to receive

hypertensive drugs during cancer treatment.

I evaluated the possible impact of long-term use of ACEIs and ARBs. Among all the patients,

301 showed a significant difference in PFS1. FOR the ACEI/ARB and non-ACEI/ARB, the p-

value was 0.002, with the recipients having a PFS1 longer with 2.4 months than the non-

recipients. The OS between the ACEI/ARB group showed no difference. There was an influence

on patients taking TKIs in PFS between the two different groups of ACEI/ARB. There was a 3.2

months longer PFS for ACEI/ARB recipients than non-recipients. Of the 73 patients who

underwent surgery, it showed no influence in any group. The OS had a significant difference in

patients taking hypertensive drugs between ACEI/ARB. And the two hundred and twenty-eight

patients with advanced NSCLC treated with platinum-based first-line therapy showed a

difference in PFs1 between the ACEI/ARB groups, with a median of 2.1 months longer, but the

OS was the same. Eighty-two patients with advanced NSCLC showed no difference in

ACEI/ARB patients and those taking other drugs.

Article Summary

The study got some limitations in the preliminary report that ACEI/ARB amplified the

PFS in patients with NSCLC who received TKIs. The clinicians noted that ACEI/s and ARBs

positively impacted PFS and Os, no matter which stage was cancer. Moreover, a larger

population can confirm the hypothesis. This study, however, was not a good model. It missed

significant parts in the medical field, including quality of life, toxicity, and compliance.
 Concerns

This study was crucial in the health of the people. Cancer is becoming the number one

killer disease in the world. The research method gives specialists information on treating patients

with the trial and error stage, saving many cancer patients' lives. The study was done well with

minimum concern, just little flaws like not indicating the side effects. The experimenters were

not supposed to assume side effects; they could have recorded them for further research.

Personal Interests

The paper was of interest to me because I have a heart for people. It is sad when I see

patients struggling with cancer, and then we administer a treatment that we are not sure will

work. Assuratity of treatment gives the patients hope. Doctors get motivated to save patients. A

positive outcome is an indication that one day we will fight and win cancer.